# A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

> **NCT00269113** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 360 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** rituximab [MabThera/Rituxan]
- **DRUG:** Standard chemotherapy

## Key facts

- **NCT ID:** NCT00269113
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-09
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2015-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00269113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00269113, "A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT00269113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*